Endocrinology: Clinical Research Program

Endocrinology: Clinical Studies Open For Enrollment

• A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5)
• A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with an Inadequate Response to Human Growth Hormone
  

 

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5)

Eligibility

• Male or female, 18 Years and older
• Have a BMI ≥35 kg/m2 at screening (Visit 1)
• No T2D diagnosis with an HbA1c <6.5% (<48 mmol/mol), as determined by the central laboratory at screening (Visit 1), OR T2D diagnosis with an HbA1c ≥6.5% to ≤9.5% (≥48 mmol/mol to ≤80 mmol/mol), as determined by the central laboratory at screening (Visit 1)
• Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
• IOCBP must not be pregnant, intending to be pregnant, breastfeeding, or intending to breastfeed
• Exclusion Criteria  
  • Have a self-reported change in body weight >5 kg (11 pounds) within 90 days before screening (Visit 1)
  • Have a prior or planned surgical treatment for obesity
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity.
  • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had within the past 90 days before screening:
    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • coronary revascularization
    • hospitalization for unstable angina, or
    • hospitalization due to congestive heart failure
  • Have New York Heart Association Functional Classification Class IV congestive heart failure
  • Have a history of chronic or acute pancreatitis
    

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT06662383

Principal Investigator

Michael Goldberg, MD

Contact for Study Screening

Nooshin.Tavoosi@wmchealth.org

 

A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with an Inadequate Response to Human Growth Hormone

Eligibility

• Male or female, must be ≥ 3 years old, and < 10 years old (females) or < 11 years old (males), at the time of signing the informed consent form (ICF), with a date of birth which ensures they will still meet the age criteria at randomization.
• A genetically confirmed diagnosis of Turner syndrome, SHOX deficiency or Noonan syndrome.
• A height assessment corresponding to a height Z-score of ≤ -2.00 SDs in reference to the general population of the same age and sex, as calculated using the CDC growth charts (https://www.cdc.gov/growthcharts/zscore.htm).
• Tanner Stage 1, at time of signing the ICF (or under 5 years of age).
• Have been receiving continuous hGH for the treatment of short stature associated with their condition for a minimum of 1 year immediately prior to enrollment and be receiving a dose of ≥ 0.35 mg/kg weekly with no dose changes in the last 6 months, and no future dose changes planned.
• Are willing to continue on hGH at their current dose for the Baseline Growth Phase, and for 24 months treatment after randomization if randomized to the hGH group.
• Inadequate response to prior hGH treatment as assessed with documented growth data and confirmed with an AGV (calculated using the difference in height between Screening Visit height and the most recent height measurement obtained in the prior 5 to12 months) that is less than that of age- and sex-matched average stature AGV determined using median heights from CDC growth charts.
• Exclusion Criteria  
  • Participants with Turner syndrome known to have Y-chromosome material unless they have undergone gonadectomy and have fully external female genitalia.
  • Diagnosis of systemic disease or condition that may cause short stature other than Turner syndrome, SHOX deficiency, or Noonan syndrome, eg, renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease. Children with such diagnoses can be considered for inclusion if their condition is well controlled, at the discretion of the BioMarin Medical team.
  • Bone age advanced beyond chronological age by more than 2 years assessed using left hand postero-anterior (PA) X-rays, by the Greulich and Pyle method.
  • Congenital heart disease which places the participant at increased risk of an adverse cardiac outcome in the setting of hypotension
  • A clinically significant finding or arrhythmia on baseline ECG that indicates abnormal cardiac function or conduction or QTc-F > 450 msec.
  • Any clinically significant abnormality on Screening tests as determined by the principal investigator (PI). Abnormal Screening labs may be repeated up to 3 months after the Screening Visit. If those labs are normal on repeat, the participant may proceed into the study.
  • Have an unstable condition likely to require surgical intervention during the study.
  • Evidence of decreased growth velocity (AGV < 1.5 cm/year) as assessed over a period of at least 6 months and growth plate closure assessed using bilateral lower extremity X-rays.
  • Vitamin D deficiency (concentration of blood 25-hydroxyvitamin D < 12 ng/mL or < 30 nmol/L) at Screening. Note: participants with blood 25-hydroxyvitamin D below the indicated threshold may receive supplementation and be re-screened after 8 weeks.
    

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT06668805

Principal Investigator

Shilpa Mehta, MD

Contact for Study Screening

Zachary_Messer@nymc.edu